SL
ENGN icon

Siren LLC’s enGene Therapeutics ENGN Stock Holding History

Siren LLC’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8M Buy
6,256,662
+1,003,503
+19% +$4.09M 0.22% 67
2026
Q1 		$35.8M Buy
5,253,159
+1,916,895
+57% +$17.1M 0.99% 30
2025
Q4 		$30.1M Buy
+3,336,264
New +$26.7M 0.9% 32

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Siren LLC's ENGN Position: Q2 2026 in Review

Siren LLC increased its enGene Therapeutics (ENGN) stake by 19% in Q2 2026, buying an estimated $4.09M and bringing the position to 6,256,662 shares worth $10.8M. The position accounts for 0.22% of the portfolio, ranked #67.

Siren LLC first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $35.8M in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Siren LLC held 6,256,662 shares of enGene Therapeutics worth $10.8M as of Q2 2026.
  • Siren LLC bought 1,003,503 enGene Therapeutics shares in Q2 2026, an estimated $4.09M.
  • enGene Therapeutics made up 0.22% of Siren LLC's portfolio in Q2 2026, its #67 holding.
  • Siren LLC first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Siren LLC's enGene Therapeutics position peaked at $35.8M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.